|
|
 |
|
Viewing report
|
|
|
|
Nitric Oxide - Therapeutics, Markets and Companies
Jain PharmaBiotech, Nov 2009, Pages: 272
This report describes the latest concepts of the role of nitric oxide (NO) in health and disease as a basis for therapeutics and development of new drugs. Major segments of the market for nitric oxide-based drugs are described as well as the companies involved in developing them.
Nitric oxide (NO) can generate free radicals as well as scavenge them. It also functions as a signaling molecule and has an important role in the pathogenesis of several diseases. A major focus is delivery of NO by various technologies. Another approach is modulation of nitric oxide synthase (NOS), which converts L-arginine to NO. NOS can be stimulated as well as inhibited by pharmacological and gene therapy approaches.
Important therapeutic areas for NO-based therapies are inflammatory disorders, cardiovascular diseases, erectile dysfunction, inflammation, pain and neuroprotection. The first therapeutic use of NO was by inhaltion for acute respiratory distress syndrome (ARDS). NO-donors, NO-mimics and NOS modulators are described and compared along with developmental status. NO-related mechanisms of action in existing drugs are identified.
Various pharmacological approaches are described along with their therapeutic relevance. Various approaches are compared using SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis. NO-based therapies are compared with conventional approaches and opportunities for combination with modern biotechnology approaches are described.
Share of drugs where NO is involved in the mechanism of action is analyzed in the worldwide pharmaceutical market for 2008 and is projected to 2013 and 2018 as new drugs with NO-based mechanisms are introduced into the market. Various strategies for developing such drugs are discussed.
Several companies have a product or products involving NO and free radicals. The report includes profiles of 40 companies involved in this area of which 11 have a significant interest in NO-based therapeutics. Other players are pharmaceutical and biotechnology companies as well as suppliers of products for NO research. Unfulfilled needs in the development of NO-based therapeutics are identified. Important 19 collaborations in this area are tabulated.
As of the end of 2008, there are over 92,000 publications relevant to NO. Selected 500 references are included in the bibliography. The text is supplemented with 26 tables and 22 figures.It is concluded that the future prospects for NO-based therapies are bright and fit in with biotechnology-based approaches to modern drug discovery and development. It is anticipated that some of these products will help in meeting the unfulfilled needs in human therapeutics.
Customers who bought this item also bought
Gene Therapy - Technologies, Markets and Companies
Alzheimer Disease - New Drugs, Markets and Companies
Pain Therapeutics - Drugs, Markets and Companies
Cell Therapy - Technologies, Markets and Companies
The Cardiovascular Disorders Market Outlook to 2012
Neuroprotection - Drugs, Markets and Companies
Food, Nutrition and the Nitric Oxide Pathway:Biochemistry and Bioactivity
Cardiovascular Drug Delivery - Technologies, Markets and Companies
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management
Bringing Drugs to Market The role of CRM in improving sales & marketing (Review Report)
The Role of Pharmacogenomics in Personalized Medicine
|
|
|
|
